Salta al contenuto principale
Passa alla visualizzazione normale.

Clinical Trial 2022

13-giu-2022

Ascolta

 

 

Title Obicetrapib and Cardiovascular Outcomes: A Placebo-Controlled, Double- Blind, Randomized Phase 3 Study to Evaluate the Effect of 10 mg Obicetrapib in Participants With Atherosclerotic Cardiovascular Disease (ASCVD) Who are Not Adequately Controlled Despite Maximally Tolerated Lipid-Modifying Therapies
NCT Number 2021-005092-39 (EudraCT)
Conditions atherosclerotic cardiovascular disease (ASCVD)
Interventions  
Sponsor/Collaborators NewAmsterdam Pharma B.V.
Gender All
Age 18 years of age at Screening (Visit 1)
Phases Phase 3
Enrollment 9000 participants
Study Type Therapeutic confirmatory (Phase III)
Study Designs Controlled
Randomised
Double blind
Start Date 12/04/2022
Completion Date 07/12/2026
Locations Prof. Maurizio Averna, A.O.U. Policlinico P. Giaccone di Palermo
URL https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-005092-39/IT 

 

 

Title ASSURE: An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects With Primary Biliary Cholangitis (PBC)
NCT Number NCT03301506
CB8025-31731
Prot. Cb8025-31731-Re ­
Codice Eudract: 2020-005198-29
Conditions  
Interventions Parallel Assignment
Sponsor/Collaborators CymaBay Therapeutics, Inc.
Gender All
Age 18 Years to 75 Years   (Adult, Older Adult)
Phases  
Enrollment 500 participants
Study Type Interventional
                 (Clinical Trial)
Study Designs Allocation: Non-Randomized | Intervention Model: Parallel Assignment | Masking: None (Open Label) | Primary Purpose: Treatment
Start Date 12/12/2017
Completion Date 01/12/2025
Locations

Sperimentatore: Prof.ssa V. Calvaruso;
Centro: U.O.C. di Gastroenterologia ed Epatologia A.O.U. Policlinico P. Giaccone di Palermo;
Promotore: CymaBay Therapeutics, Inc.
CRO: PPD Italy s.r.l.

URL https://clinicaltrials.gov/ct2/show/NCT03301506 

 

 

Title TRANSFORM: A 52-week, Randomized, Placebo-controlled, Double-blind, Adaptive Phase 2b/3 Trial of Setanaxib With a 52-week Extension Phase in Patients With Primary Biliary Cholangitis (PBC) and Elevated Liver Stiffness
NCT Number NCT05014672
GSN000350
2021-001810-13 ( EudraCT Number )
Conditions Primary Biliary Cholangitis
Liver Stiffness
Interventions Parallel Assignment
Sponsor/Collaborators Calliditas Therapeutics Suisse SA
Gender All
Age 18 Years and older   (Adult, Older Adult)
Phases Phase 2
Phase 3
Enrollment 318 participants
Study Type Interventional
 (Clinical Trial)
Study Designs Allocation: Randomized | Intervention Model: Parallel Assignment | Intervention Model Description: Placebo-controlled 1:1:1 in double blind treatment period with 1:1 reassignment to setanaxib in extension period | Masking: Double (Participant, Investigator)
Start Date 14/02/2022
Completion Date 15/09/2025
Locations Sperimentatore: Dott.ssa V. Calvaruso Centro: U.O.C. di Gastroenterologia Promotore: Genkyotex Suisse SA CRO: Pharmaceutical Research Associates Italy S.r.l.
URL https://clinicaltrials.gov/ct2/show/NCT05014672 

 

 

Title An Open-Label Extension Study of AKCEA-APOCIII-LRx Administered Subcutaneously to Patients With Familial Chylomicronemia Syndrome (FCS)
NCT Number NCT05130450 - (EudraCT Number: 2021-003280-95)
Conditions Familial Chylomicronemia Syndrome
Interventions Drug: Olezarsen
Sponsor/Collaborators Ionis Pharmaceuticals, Inc.
Gender All
Age 18 Years and older (Adult, Older Adult)
Phases Phase 3
Enrollment 60
Study Type Interventional
Study Designs Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Start Date 18/11/2021
Completion Date 30/04/2025
Locations

Italy
UOC di Farmacia AOUP PAOLO GIACCONE - Palermo, Italy, 90127 

 

and other 11 international study locations

URL https://ClinicalTrials.gov/show/NCT04568434 

 

 

Title A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of ISIS 678354 Administered Subcutaneously to Patients With Severe Hypertriglyceridemia
NCT Number NCT05079919 - (EudraCT Number: 2021-002192-19)
Conditions Severe Hypertriglyceridemia
Interventions Drug: Olezarsen
Drug: Placebo
Sponsor/Collaborators Ionis Pharmaceuticals, Inc.
Gender All
Age 18 Years and older (Adult, Older Adult)
Phases Phase 3
Enrollment 540
Study Type Interventional
Study Designs Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Start Date 25/10/2021
Completion Date 28/02/2025
Locations

Italy
Ospdale E. Bassini - Milano, Italy, 20092
A.O. Policlinico Universitario P. Giaccone - Palermo, Italy, 90127
Policlinico Umberto - Roma, Italy, 00161 

and other 94 international study locations

URL https://ClinicalTrials.gov/show/NCT05079919 

 

 

Title Impact of Extra Virgin Olive Oil (EVOO) With Health Properties in Improving the Overall Health Status and Preventing Cardiovascular Risk in Metabolic Syndrome
NCT Number NCT05282316
Conditions Metabolic Syndrome
Interventions Dietary Supplement: EVOO polyphenols enriched
Dietary Supplement: EVOO standard
Sponsor/Collaborators University of Palermo
Gender All
Age 18 Years and older (Adult, Older Adult)
Phases Phase 3
Enrollment 90
Study Type Interventional
Study Designs Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Double-blind placebo-controlled
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description: Same organoleptic features of the two different kind of EVOO (polyphenols enriched and standard).
Primary Purpose: Prevention
Start Date 18/02/2022
Completion Date 31/12/2024
Locations

Italy
Department of Internal Medicine, University Hospital of Palermo Recruiting
Palermo, Italy, 90127
Contact: Aurelio Seidita, MD +390916554710 aurelio.seidita@unipa.it
Contact: Maurizio Soresi, MD +390916554710 maurizio.soresi@unipa.it
Sub-Investigator: Lydia Giannitrapani, MD

URL https://ClinicalTrials.gov/show/NCT05282316  

 

 

Title Semaglutide Cardiovascular Outcomes Trial in Patients With Type 2 Diabetes
NCT Number NCT03914326
EX9924-4473

2018-003141-42 ( Registry Identifier: European Medicines Agency (EudraCT) )

U1111-1218-5368 ( Other Identifier: World Health Organization (WHO) )
Conditions Diabetes Mellitus, Type 2
Interventions Parallel Assignment
Sponsor/Collaborators Novo Nordisk A/S
Gender All
Age 50 Years and older   (Adult, Older Adult)
Phases Phase 3
Enrollment 9642 participants
Study Type Interventional
 (Clinical Trial)
Study Designs Allocation: Randomized | Intervention Model: Parallel Assignment | Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) | Masking Description: Sponsor staff involved in the clinical trial is masked according to company standard procedures
Start Date 17/06/2019
Completion Date 29/07/2024
Locations A.O.U. Policlinico P. Giaccone di Palermo
URL https://clinicaltrials.gov/ct2/show/NCT03914326 

 

 

Title Reparixin 1200 mg TID as add-on to SoC to Limit Disease Progression in Hospitalised Patients With COVID-19 and Other Community-Acquired Pneumonia. A Multicentre, Randomised, Double-blinded, Placebo-controlled, Phase III Trial (REPAVID-22)
NCT Number NCT05254990
Conditions Infectious Pneumonia
Severe COVID-19
Interventions Parallel Assignment
Sponsor/Collaborators Dompé Farmaceutici S.p.A.
Gender All
Age 18 Years and older   (Adult, Older Adult)
Phases Phase 3
Enrollment 526 participants
Study Type Interventional
 (Clinical Trial)
Study Designs Allocation: Randomized | Intervention Model: Parallel Assignment | Intervention Model Description: male and female patients >18 years, hospitalised for COVID-19, will be assigned (1:1) to receive either oral reparixin (treatment group) or matched placebo (control group) three times a day (TID) for up to 21 days. | Masking: Triple (Participant, Care Provider, Investigator)
Start Date 06/04/2022
Completion Date 01/03/2024
Locations Sperimentatore: Prof. N. Scichilone Centro: U.O.C. di Pneumologia
URL https://clinicaltrials.gov/ct2/show/NCT05254990 

 

 

Title Prospective Randomized Study on the Feasibility of Allogeneic Stem Cell Transplantation in Higher-risk-myelodysplastic Syndromes, Performed Upfront or Preceded by Azacitidine or Conventional Chemotherapy According to the BM-blast Proportion
NCT Number NCT04184505
MDS 0519
Codice Eudract: 2019-003997-25
Conditions High-risk MDS
Interventions Parallel Assignment
Sponsor/Collaborators Gruppo Italiano Malattie EMatologiche dell'Adulto
Gender All
Age 18 Years to 70 Years   (Adult, Older Adult)
Phases Phase 3
Enrollment 274 participants
Study Type Interventional
 (Clinical Trial)
Study Designs Allocation: Randomized | Intervention Model: Parallel Assignment | Masking: None (Open Label) | Primary Purpose: Treatment
Start Date 27/11/2020
Completion Date 01/03/2024
Locations Sperimentatore: Prof. S. Siragusa Centro: U.O.C. di Ematologia Sponsor: Fondazione GIMEMA Franco Mandelli Onlus
URL https://clinicaltrials.gov/ct2/show/NCT04184505 

 

 

Title A Multi-centre, Prospective, Non-interventional Single-arm Study Investigating Clinical Parameters Associated With the Use of Once-daily Oral Semaglutide in a Real-world Adult Population With Type 2 Diabetes in Italy
NCT Number NCT05230615
Conditions Diabetes Mellitus, Type 2
Interventions Drug: Oral semaglutide
Sponsor/Collaborators Novo Nordisk A/S
Gender All
Age age above or equal to 18 years 
Phases  
Enrollment 462
Study Type Observational
Study Designs Observational Model: Cohort
Time Perspective: Prospective
Start Date 01/04/2022
Completion Date 03/11/2023
Locations Sperimentatore: Prof. ssa Carla Giordano Centro: U.O.C. di Endocrinologia Sponsor: Novo Nordisk A/S CRO: IQVIA
URL https://clinicaltrials.gov/ct2/show/NCT05230615 

 

 

Title A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of AKCEA-APOCIII-LRx Administered Subcutaneously to Patients With Familial Chylomicronemia Syndrome (FCS)
NCT Number NCT04568434 - (EudraCT Number: 2020-002536-67)
Conditions Familial Chylomicronemia Syndrome
Interventions Drug: Olezarsen
Drug: Placebo
Sponsor/Collaborators Sponsor: Ionis Pharmaceuticals, Inc.
Collaborator: Akcea Therapeutics
Gender All
Age 18 Years and older (Adult, Older Adult)
Phases Phase 3
Enrollment 66
Study Type Interventional
Study Designs Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Start Date 16/11/2020
Completion Date 31/10/2023
Locations

Italy
ASST Grande Ospedale Metropolitano Niguarda - Milano, Italy, 20162
Azienda Ospedaliera Universitaria Federico II - Napoli, Italy, 80131
Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone - Palermo, Italy, 90127
Azienda Ospedaliero Universitaria Policlinico Umberto I - Roma, Italy, 00161 

 

and other 48 international study locations

URL https://ClinicalTrials.gov/show/NCT04568434

 

 

Title Contribution of KIR Genes on the Genetic Predisposition to Non-Celiac Wheat Sensitivity
NCT Number NCT05469971
Conditions Non-celiac Wheat Sensitivity
Interventions Genetic: KIR genotyping
Sponsor/Collaborators Pasquale Mansueto, University of Palermo
Gender All
Age 18 Years to 65 Years   (Adult, Older Adult)
Phases  
Enrollment 150 participants
Study Type Observational
Study Designs Observational Model: Case-Control
Time Perspective: Retrospective
Start Date 01/11/2022
Completion Date 30/09/2023
Locations Pasquale Mansueto, University of Palermo
URL https://clinicaltrials.gov/ct2/show/NCT05469971

 

 

Title Randomised, Open-label and Parallel Group Trial to Investigate the Effects of Oral BI 685509 Alone or in Combination With Empagliflozin on Portal Hypertension After 8 Weeks Treatment in Patients With Clinically Significant Portal Hypertension (CSPH) in Compensated Cirrhosis
NCT Number NCT05282121
1366-0029
2021-005171-40 ( EudraCT Number )
Conditions Liver Diseases
Hypertension, Portal
Interventions Parallel Assignment
Sponsor/Collaborators Boehringer Ingelheim
Gender All
Age 18 Years to 75 Years   (Adult, Older Adult)
Phases Phase 2
Enrollment 80 participants
Study Type Interventional
 (Clinical Trial)
Study Designs Allocation: Randomized | Intervention Model: Parallel Assignment | Masking: None (Open Label) | Primary Purpose: Treatment
Start Date 26/05/2022
Completion Date 28/07/2023
Locations Sperimentatore: Prof.ssa V. Calvaruso Centro: U.O.C. di Gastroenterologia
URL https://clinicaltrials.gov/ct2/show/NCT05282121 

 

 

Title A Phase 3 Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine-Experienced Adults 50 Years of Age or Older
NCT Number NCT05420961
V116-006
jRCT2071220025 ( Registry Identifier: jRCT )
2021-006679-41 ( EudraCT Number )
Conditions Pneumonia, Pneumococcal
Interventions Parallel Assignment
Sponsor/Collaborators Merck Sharp & Dohme LLC
Gender All
Age 50 Years and older   (Adult, Older Adult)
Phases Phase 3
Enrollment 700 participants
Study Type Interventional
                 (Clinical Trial)
Study Designs Allocation: Randomized | Intervention Model: Parallel Assignment | Masking: Double (Participant, Investigator) | Masking Description: Cohorts 1 and 2: participants, investigator, sponsor Cohort 3: no blinding
Start Date 12/07/2022
Completion Date 18/05/2023
Locations A.O.U. Policlinico P. Giaccone di Palermo: Claudio Costantino (MED/42), Francesco Vitale (MED/42), Carmelo Massimo Maida (MED/42), Fabio Tramuto (MED/42), Vincenzo Restivo (MED/42)
URL https://clinicaltrials.gov/ct2/show/NCT05420961

 

 

Title A Multicenter, Cross-sectional Study to Characterize the Distribution of Lipoprotein(a) Levels Among Patients With Documented History of Atherosclerotic Cardiovascular Disease
NCT Number NCT05378529
Conditions Atherosclerotic Cardiovascular Disease
Interventions Other: Lp(a) Screening
Sponsor/Collaborators Amgen
Gender All
Age 18 Years to 85 Years (Adult, Older Adult)
Phases Not Applicable
Enrollment 40000
Study Type Interventional
Study Designs Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Start Date 19/04/2022
Completion Date 22/05/2023
Locations

Italy
Azienda Ospedaliero Universitaria di Bologna Policlinico S Orsola Malpighi - Bologna, Italy, 40138
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia - Brescia, Italy, 25123
Azienda Ospedaliera Sant Anna e San Sebastiano - Caserta, Italy, 81100
Azienda Ospedaliera Universitaria di Ferrara Arcispedale Sant Anna - Ferrara, Italy, 44124
Ospedale Policlinico San Martino IRCCS - Genova, Italy, 16132
IRCCS Centro Cardiologico Monzino - Milano, Italy, 20138
Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda - Milano, Italy, 20162
Azienda Ospedaliera Universitaria Maggiore della Carita - Novara, Italy, 28100
Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone - Palermo, Italy, 90127
Fondazione Policlinico Tor Vergata - Roma, Italy, 00133
IRCCS Istituto Clinico Humanitas - Rozzano MI, Italy, 20089
Azienda Ospedaliera Ordine Mauriziano di Torino - Torino, Italy, 10128

and other 607 international study locations

URL https://ClinicalTrials.gov/show/NCT05378529 

 

 

Title A Double-blind, Randomized, Placebo-controlled Phase 2 Study to Evaluate Efficacy, Safety, and Tolerability of Olpasiran (AMG 890) in Subjects With Elevated Lipoprotein(a)
NCT Number NCT04270760
20180109

2019-003688-23 ( EudraCT Number )
Conditions  
Interventions Parallel Assignment
Sponsor/Collaborators Amgen
Gender All
Age 18 Years to 80 Years   (Adult, Older Adult)
Phases  
Enrollment 700 participants
Study Type Interventional
 (Clinical Trial)
Study Designs Allocation: Randomized | Intervention Model: Parallel Assignment | Masking: Double (Participant, Investigator) | Primary Purpose: Treatment
Start Date 28/07/2020
Completion Date 18/05/2023
Locations A.O.U. Policlinico P. Giaccone di Palermo
URL https://clinicaltrials.gov/ct2/show/NCT04270760

 

 

Title Not-celiac Wheat Sensitivity (NCWS) in Patients With Irritable Bowel Syndrome. Randomized Double-Blind Placebo-Controlled Trial (Wheat vs Placebo) for Bio-markers Identification of NCWS and Understanding Its Pathogenetic Mechanisms.
NCT Number NCT01762579
Conditions Not-celiac Wheat Sensitivity
Interventions Parallel Assignment
Dietary Supplement: wheat flour
Dietary Supplement: Xylose
Sponsor/Collaborators Pasquale Mansueto, University of Palermo
Gender All
Age 18 Years to 65 Years   (Adult, Older Adult)
Phases  
Enrollment 100 participants
Study Type Interventional
 (Clinical Trial)
Study Designs Allocation: Randomized | Intervention Model: Parallel Assignment | Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) | Primary Purpose: Diagnostic
Start Date 01/01/2012
Completion Date 01/01/2023
Locations Internal Medicine, University Hospital
Palermo, Italy, 90100
Contact: Antonio Carroccio, PHD
Contact: Pasquale Mansueto, MD
Sub-Investigator: Alberto D'Alcamo, MD
Sub-Investigator: Giusi Randazzo, MD
Sub-Investigator: Miriam Carta, MD
Sub-Investigator: Giuseppe Taormina, MD 
URL https://clinicaltrials.gov/ct2/show/NCT01762579

 

 

 

Elenco altri Trial approvati dal Comitato Etico Palermo 1 di cui è in corso il reperimento nelle Banche Dati

Data TRIAL
14/06/2022 Progetto Madonie – progetto per la caratterizzazione di pazienti a rischio cardiovascolare moderato, alto e molto alto e pazienti affetti da ipercolesterolemia familiare
01/01/2022 - 31/12/2022 Treatment of High and Very high riSk dyslipidemic pAtients for the PreveNTion of CardiOvasculaR Events in Europe – a MultInatioNal ObservatIonal Study (SANTORINI)
01/01/2022 - 31/12/2022 Time-course dei livelli plasmatici di PCSK9 in pediatria
01/01/2022 - 31/12/2022 Treatment of High and Very high riSk dyslipidemic pAtients for the PreveNTion of CardiOvasculaR Events in Europe – a MultInatioNal ObservatIonal Study (SANTORINI)
06/05/2020 - 07/02/2022 Clinical characteristics and pathogenic mechanisms of anemia in Non-Celiac Wheat Sensitivity compared to Celiac Disease and Irritable
Bowel Syndrome
31/12/2022 Adesione Alla Vaccinazione Anti-Papillomavirus Nelle Donne Con Accesso Allo Screening Del Tumore Della Cervice Uterina: Studio Cross-Sectional Basato Sul Modello Comportamentale Health Action Process Approach
31/12/2022 Confronto Del Rischio Di Insufficienza Renale Acuta Nei Pazienti Sottoposti Alla Terapia Di Combinazione Piperacillina Tazobactam E Vancomicina (Tzp-Van) Vs Piperacillina Tazobactam E Teicoplanina (Tzp-Tei). Prot. Concomitant
31/12/2022 Dieta Chetogenetica Ipocalorica, Normoproteica, Ipoglucidica (Vlckd) Nella Malattia Di Cushing
31/12/2022 Differenze Legate Al Sesso Nella Presentazione Clinica, Trattamento E Prognosi Dei Tumori Neuroendocrini Con Sindrome Da Carcinoide: Studio Retrospettivo Multicentrico
31/12/2022 Effetti Dell'Implementazione Del Myo-Nositolo, Citrato Di Magnesio, Citrato Di Potassio, Acido 5-Metiltetraidrofolico, Vitamina C E Vitamine Del Gruppo B Sul Controllo Metabolico E Sugli Esiti Avversi Materno-Fetali In Gravidanza Nelle Donne Con Diabete Gestazionale
31/12/2022 Effetti Dell'Implemetazione Del Myo-Inositolo Citrato Di Magnesio, Citrato Di Potassio, Acido 5 Metiltetraidrofolico, Vitamina C E Vitamine Del Gruppo B Sul Controllo Metabolico E Sugli Esiti Avversi Materno- Fetali In Gravidanza Nelle Donne Con Diabete Gestazionale
31/12/2022 Ingegnerizzazione Della Valvola Mitrale: Controllo Bio-Ispirato Della Struttura E Della Funzione, Da Cadavere, Per Migliorare Le Prestazioni In Vivo. Prot. Biomitral
31/12/2022 Integrazione Del Mioinositolo Nel Trattamento Del Diabete Mellito Gestazionale: Effetti Sul Controllo Glicemico E Sulle Complicanze Materno-Fetali
31/12/2022 Ipovitaminosi D Nei Pazienti Con Malattia Di Cushing: Prima E Dopo La Supplementazione Con Vitamina D
31/12/2022 Monitoraggio Immunologico Post-Vaccinazione Anti Covid-19 In Particolari Gruppi Di Popolazione Italiana
31/12/2022 Pioglitazione Per Il Trattamento Di Pazienti Con Steatoepatite Non Alcolica: Meta-Analisi Per Dati Individuali Da Trial Clinici
31/12/2022 Prevenzione E Management Di Covid -19 In Rsa
31/12/2022 Progetto Prevenzione Incidenti Domestici E Promozione Attivita' Fisica Nell'Anziano
31/12/2022 Real Life Experience Of Knowledge Attitudes And Acceptance Rate Of Covid-19 And Influenza Vaccine Administration In One Of The Main Vaccination Hub Of Sicilian Region, Italy At The University Hospital Of Palermo
31/12/2022 Registro Clinico Europeo Prospettico, Multicentrico, Non Interventistico, Non Comparativo Per Valutare L'Esito Clinico E La Sicurezza Del Trattamento Di Pazienti Gravemente Infetti Con Fosfomicina E.V. Prot. Fortress
31/12/2022 Sjogren Syndrome: Biomarkers, Co-Morbidities Development Of Malignant Non-Hodgkin'S Lymphoma
31/12/2022 Spi-62 Come Trattamento Per L'Ipercortisolismo Correlato A Un Tumore Surrenale Benigno Prot. Spi-62 Cl-2002 ­ Codice Eudract: 2022-000748-32
31/12/2022 Spondiloatriti: Esperienza Monocentrica Per Valutare Efficacia E Sicurezza Delle Terapie Ad Oggi Approvate Attraverso Un Approccio Multidisciplinare Che Prevede Studio Clinico, Laboratoristico, Strumentale E Valutazione Del Rischio Cardiovascolare E Del Coinvolgimento Tramite Esame Endoscopico Gastrointestinale
31/12/2022 Stato Di Salute Orale In Soggetti Con Fragilita' Multidimensionale
31/12/2022 Studio Adattivo Di Fase Iv Randomizzato, In Aperto, Multicentrico Per Determinare La Sicurezza E L'Efficacia Di Diversi Anticorpi Monoclonali (Moabs) Contro La Sars-Cov-2 Per Il Trattamento Precoce Del Covid-19 In Pazienti Adulti Non Ospedalizzati (Studio Monet)
31/12/2022 Studio Cross Sectional Sullo Status Vaccinale E Sulle Conoscenze Delle Vaccinazioni Raccomandate In Gravidanza E Nel Post-Partum In Un Campione Rappresentativo Di Puerpere Della Provincia Di Palermo
31/12/2022 Studio Della Perturbazione Intestinale Indotta Da Antibiotici Come Fattore Terapeutico Nell'Immunita' Antitumorale
31/12/2022 Studio Dell'Effetto Apoptotico Di Estratti Di Fumo Di Sigaretta In Eritrociti Umani Isolati
31/12/2022 Studio Osservazionale Sulla Funzionalita' Respiratoria Dei Pazienti Dimessi Con Diagnosi Di Coronavirus (Covid-19) Nel Lungo Termine. Sars-Cov2 Reflow Prot. Sars-Cov2 Reflow
31/12/2022 Studio Retrospettivo Per La Caratterizzazione Del Microbiota Intestinale In Associazione A Patologie E Alla Dieta Alimentare Nella Popolazione Italiana
31/12/2022 Studio Trasversale Sui Livelli Di Lipoproteina (A) Nei Pazienti Con Anamnesi Documentata Di Malattia Cardiovascolare Aterosclerotica (Ascvd). Prot. 20210057
31/12/2022 Studio: Validazione di un questionario sul self-care nei pazienti con malattie mieloproliferative croniche philadelphianegative. Prot. Self-Care_Aipamm
31/12/2022 Trial sul campo per la valutazione dell'efficacia di un servizio di counselling attivo sull'allattamento al seno tramite il trans theoretical model
31/12/2022 Utilizzo a lungo termine dell'albumina in pazienti con cirrosi epatica. prot. real-answear
31/12/2022 Vaccinazione Anti-Influenzale E Cosomministrazioni Raccomandate Nelle Categorie A Rischio Complicanze (Campagna Vaccinale 2022 ­ 2023)
31/12/2022 Validazione di un nuovo strumento multidimensionale nell'anziano: L'Aged Care Technology Tool
19/04/2022 -22/05/2023 A Multicenter, Cross-sectional Study to Characterize the Distribution of Lipoprotein(a) Levels Among Patients With Documented History of Atherosclerotic Cardiovascular Disease
16/11/2020 - 31/10/2023 A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of AKCEA-APOCIII-LRx Administered Subcutaneously to Patients With Familial Chylomicronemia Syndrome (FCS)
25/10/2021 - 28/02/2025 A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of ISIS 678354 Administered Subcutaneously to Patients With Severe Hypertriglyceridemia
18/11/2021 - 30/04/2025 An Open-Label Extension Study of AKCEA-APOCIII-LRX AdministeredSubcutaneously to Patients with Familial Chylomicronemia Syndrome(FCS)(ISIS 678354-CS13)